• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

早期乳腺癌的辅助地舒单抗治疗——证据与争议。

Adjuvant denosumab for early breast cancer-Evidence and controversy.

机构信息

Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy.

Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy.

出版信息

Breast. 2024 Dec;78:103826. doi: 10.1016/j.breast.2024.103826. Epub 2024 Oct 23.

DOI:10.1016/j.breast.2024.103826
PMID:39509862
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11570850/
Abstract

The efficacy of adjuvant denosumab in combination with hormonotherapy in breast cancer patients was investigated in two randomized trials, ABCSG-18 and D-Care, but the results were mixed with respect to the impact of this drug on disease-free survival. However, the ABCSG-18 study has achieved its primary goal: prevention of clinical fractures. Therefore, the protective role of Denosumab on bone fragility induced by estrogen deprivation, already demonstrated in post-menopausal women, has been validated in the breast cancer setting.

摘要

两项随机试验（ABC 研究 18 期和 D-Care 研究）研究了辅助性地舒单抗联合激素治疗乳腺癌患者的疗效，但该药物对无病生存期的影响结果不一。然而，ABC 研究 18 期已经达到了其主要目标：预防临床骨折。因此，地舒单抗预防雌激素剥夺引起的骨脆弱性的保护作用已经在绝经后妇女中得到证实，在乳腺癌环境中也得到了验证。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd27/11570850/abfd1e416bb4/gr1b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd27/11570850/92ba175af5db/gr1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd27/11570850/abfd1e416bb4/gr1b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd27/11570850/92ba175af5db/gr1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd27/11570850/abfd1e416bb4/gr1b.jpg

相似文献

1
Adjuvant denosumab for early breast cancer-Evidence and controversy.早期乳腺癌的辅助地舒单抗治疗——证据与争议。
Breast. 2024 Dec;78:103826. doi: 10.1016/j.breast.2024.103826. Epub 2024 Oct 23.
2
Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis.地诺单抗与唑来膦酸预防绝经后早期乳腺癌患者芳香化酶抑制剂相关骨折的比较；一项混合治疗的荟萃分析。
Expert Rev Anticancer Ther. 2016 Aug;16(8):885-91. doi: 10.1080/14737140.2016.1192466. Epub 2016 Jun 1.
3
Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer.抗吸收药物对绝经后早期乳腺癌妇女的骨保护和辅助作用。
Br J Clin Pharmacol. 2019 Jun;85(6):1125-1135. doi: 10.1111/bcp.13834. Epub 2019 Jan 25.
4
Sowing the soil for cure? Results of the ABCSG-12 trial open a new chapter in the evolving adjuvant bisphosphonate story in early breast cancer.为治愈播下土壤？ABCSG-12试验结果为早期乳腺癌辅助性双膦酸盐治疗的不断发展篇章开启了新的一页。
J Clin Oncol. 2009 Sep 1;27(25):4043-6. doi: 10.1200/JCO.2008.21.4908. Epub 2009 Aug 3.
5
Bisphosphonates and other bone agents for breast cancer.用于乳腺癌的双膦酸盐及其他骨治疗药物。
Cochrane Database Syst Rev. 2017 Oct 30;10(10):CD003474. doi: 10.1002/14651858.CD003474.pub4.
6
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.早期乳腺癌辅助地舒单抗治疗（D-CARE）：一项国际性、多中心、随机、对照、3 期临床试验。
Lancet Oncol. 2020 Jan;21(1):60-72. doi: 10.1016/S1470-2045(19)30687-4. Epub 2019 Dec 2.
7
Breaking away: high fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients.突破：高骨折率可能值得对斯堪的纳维亚乳腺癌患者进行辅助内分泌治疗的新试验。
Acta Oncol. 2013 May;52(4):861-2. doi: 10.3109/0284186X.2012.742963. Epub 2012 Nov 29.
8
Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.地舒单抗对接受辅助芳香化酶抑制剂治疗非转移性乳腺癌的绝经后日本女性低骨密度的影响：24 个月结果。
Breast Cancer. 2019 Jan;26(1):106-112. doi: 10.1007/s12282-018-0896-y. Epub 2018 Jul 27.
9
Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.来曲唑辅助治疗绝经后早期乳腺癌的临床疗效及安全性
J Bone Miner Metab. 2019 Sep;37(5):864-870. doi: 10.1007/s00774-018-00985-8. Epub 2019 Mar 13.
10
The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer.抗吸收疗法在改善早期和转移性乳腺癌患者护理中的作用。
Breast Cancer Res Treat. 2012 Apr;132(2):355-63. doi: 10.1007/s10549-011-1800-z. Epub 2011 Oct 11.

引用本文的文献

1
Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG.激素敏感性乳腺癌女性芳香化酶抑制剂相关骨质丢失（AIBL）的管理：国际骨质疏松基金会（IOF）、中国抗癌协会乳腺癌专业委员会（CABS）、欧洲钙化组织协会（ECTS）、国际内分泌学会（IEG）、欧洲肿瘤内科学会（ESCEO）、国际绝经学会（IMS）和国际老年肿瘤学会（SIOG）联合更新立场声明
J Bone Oncol. 2025 Jun 11;53:100694. doi: 10.1016/j.jbo.2025.100694. eCollection 2025 Aug.

本文引用的文献

1
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.《NCCN 肿瘤学临床实践指南：乳腺癌》第 3.2024 版。
J Natl Compr Canc Netw. 2024 Jul;22(5):331-357. doi: 10.6004/jnccn.2024.0035.
2
Rankl genetic deficiency and functional blockade undermine skeletal stem and progenitor cell differentiation.Rankl 基因缺失和功能阻断会破坏骨骼干细胞和祖细胞的分化。
Stem Cell Res Ther. 2024 Jul 6;15(1):203. doi: 10.1186/s13287-024-03803-3.
3
Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer.辅助地舒单抗治疗乳腺癌的长期结局。
NEJM Evid. 2022 Dec;1(12):EVIDoa2200162. doi: 10.1056/EVIDoa2200162. Epub 2022 Nov 18.
4
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.早期乳腺癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2024 Feb;35(2):159-182. doi: 10.1016/j.annonc.2023.11.016. Epub 2023 Dec 13.
5
Metastasis prevention with bone-targeted agents: a complex interaction between the microenvironment and tumour biology.骨靶向药物预防转移：微环境与肿瘤生物学之间的复杂相互作用。
J Bone Miner Metab. 2023 May;41(3):290-300. doi: 10.1007/s00774-023-01434-x. Epub 2023 May 10.
6
Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice.接受激素剥夺疗法的癌症患者椎体骨折的预测：在实际临床实践中世界卫生组织骨折风险评估工具（FRAX）和骨密度的可靠性。
J Bone Oncol. 2022 Mar 9;33:100421. doi: 10.1016/j.jbo.2022.100421. eCollection 2022 Apr.
7
Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice.NSABP B-34 研究中早期乳腺癌的扩增和辅助氯膦酸盐的结果及其对临床实践的潜在影响。
JNCI Cancer Spectr. 2021 May 28;5(4). doi: 10.1093/jncics/pkab054. eCollection 2021 Aug.
8
Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies.骨密度和FRAX评分可能无法预测接受激素剥夺治疗的癌症患者的骨折风险。
J Clin Oncol. 2020 Oct 10;38(29):3363-3366. doi: 10.1200/JCO.20.00434. Epub 2020 Jun 30.
9
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.早期乳腺癌辅助地舒单抗治疗（D-CARE）：一项国际性、多中心、随机、对照、3 期临床试验。
Lancet Oncol. 2020 Jan;21(1):60-72. doi: 10.1016/S1470-2045(19)30687-4. Epub 2019 Dec 2.
10
Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.MAF 扩增对早期乳腺癌辅助唑来膦酸治疗结局的影响：国际、开放标签、随机、对照、III 期 AZURE（BIG 01/04）试验的二次分析。
Lancet Oncol. 2017 Nov;18(11):1543-1552. doi: 10.1016/S1470-2045(17)30603-4. Epub 2017 Oct 13.